Novo Nordisk A/S
Tolerogenic DNA vaccine
Last updated:
Abstract:
The present invention relates to plasmids useful for prevention and/or delay of e.g. type 1 diabetes.
Status:
Grant
Type:
Utility
Filling date:
26 Apr 2019
Issue date:
22 Mar 2022